注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Syndax Pharmaceuticals Inc是一家臨床階段的生物製藥公司,專注於開發一系列癌症療法。該公司的主要候選產品包括SNDX-5613和SNDX-6352(axatilimab)。該公司專注於開發SNDX-5613,靶向menin與混合譜系白血病1(MLL1)的結合作用、用於治療混合譜系白血病基因重排(MLLr)、急性白血病和核磷蛋白1(NPM1)、突變急性髓細胞白血病(AML),以及阻斷集束刺激因子1(CSF-1)受體的單克隆抗體axatilimab。該公司的候選產品還包括每週一次的口服小分子恩替諾他,和I類組蛋白去乙酰化酶(HDAC)抑製劑,該抑製劑正在與依西美坦聯合進行III期E2112註冊臨床試驗,用於激素受體陽性、人表皮生長因子受體2陰性和乳腺癌評估。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Dennis G. Podlesak | 63 | 2008 | Independent Chairman |
Michael A. Metzger | 51 | 2015 | CEO & Director |
George W. Sledge | 71 | 2014 | Member of Scientific Advisory Board |
Keith A. Katkin | 52 | 2017 | Independent Director |
Pierre Legault | 62 | 2017 | Independent Director |
Joseph Paul Eder | - | 2016 | Member of Scientific Advisory Board & Chief Medical Officer |
Ronald M. Evans | 75 | 2016 | Co-Founder, Advisor and Chair of Scientific Advisory Board |
Samir N. Khleif | 60 | 2016 | Member of Scientific Advisory Board |
William Meury | 56 | 2018 | Independent Director |
Julie R. Brahmer | - | 2015 | Member of Scientific Advisory Board |
Jennifer A. Jarrett | 53 | 2018 | Independent Director |
Jedd D. Wolchok | - | 2016 | Member of Scientific Advisory Board |
Martin H. Huber | 63 | 2021 | Independent Director |
Aleksandra Rizo | 49 | 2024 | Director |
Lisa M. Coussens | - | 2017 | Member of Scientific Advisory Board |
Hope S. Rugo | - | 2016 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核